AACR: Atezolizumab Aids Some With Triple-Negative Breast CA

Share this content:
AACR: Atezolizumab Aids Some With Triple-Negative Breast CA
AACR: Atezolizumab Aids Some With Triple-Negative Breast CA

MONDAY, April 3, 2017 (HealthDay News) -- Women with advanced, triple-negative breast cancers who responded to the immunotherapy atezolizumab (Tecentriq) gained a significant survival benefit, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 1 to 5 in Washington, D.C.

The trial included 112 patients who were treated with atezolizumab, an anti-PD-L1 immunotherapy. Nineteen of the 112 study participants got atezolizumab as their first line of therapy; the other 93 had already received at least two lines of prior treatment.

Overall, the response rate to the drug was low -- just 11 of 112 patients. However, results were significant for the minority of patients who did respond, Peter Schmid, M.D., Ph.D., director of the Breast Centre at St. Bartholomew's Hospital and Barts Cancer Institute in London, said in a news release from the American Association for Cancer Research. "The most significant finding is the difference in the overall survival between patients who responded to atezolizumab and patients who did not respond," he said. "While all responders were alive after one year, the one-year survival rate for nonresponders was only 38 percent."

"Another noteworthy finding is that metastatic triple-negative breast cancer patients treated with atezolizumab had a prolonged median duration of response of 21 months, which is substantially longer than what has been seen with any other treatment to date for this patient population," Schmid added. Side effects were relatively low. According to the researchers, 11 percent of patients had serious side effects, and only 3 percent of the women stopped using atezolizumab due to side effects.

The study was funded by Genentech, the manufacturer of atezolizumab.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Risk for Interval CRC Higher in Blacks Than Whites

Risk for Interval CRC Higher in Blacks Than ...

Differences most pronounced for cancer of the distal colon and the rectum

Even Small Amounts of Alcohol Can Affect Breast Cancer Risk

Even Small Amounts of Alcohol Can Affect Breast ...

Small glass of wine each day can up odds of both premenopausal and postmenopausal breast cancer

ATS: Angiotensin II Improves BP in Vasodilatory Shock

ATS: Angiotensin II Improves BP in Vasodilatory Shock

Angiotensin II effective for vasodilatory shock in patients not responding to conventional vasopressors

is free, fast, and customized just for you!

Already a member?

Sign In Now »